|4Aug 31, 4:32 PM ET

Camac Fund, LP 4

4 · Pasithea Therapeutics Corp. · Filed Aug 31, 2022

Insider Transaction Report

Form 4
Period: 2022-08-29
Transactions
  • Purchase

    Common Stock

    2022-08-30$1.15/sh+17,828$20,4521,635,157 total(indirect: See footnote)
  • Purchase

    Common Stock

    2022-08-29$1.17/sh+5,000$5,8411,617,329 total(indirect: See footnote)
Footnotes (2)
  • [F1]The number of shares beneficially owned includes 1,000 shares inadvertently omitted from the Reporting Persons' Form 3 filed 08/15/2022.
  • [F2]The shares are held by Camac Fund, LP. ("Camac Fund"). Eric Shahinian is the managing member of Camac Capital, LLC, which is the general partner of Camac Fund and the managing member of Camac Partners, LLC.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION